Medtronic Stock Price, News & Analysis

Medtronic (NYSE: MDT) has announced that its planned spinoff diabetes business will be named MiniMed, reviving the original name of the company acquired by Medtronic in 2001. The separation is expected to complete within 18 months, subject to various conditions. MiniMed, to be based in Northridge, California, will operate with over 8,000 employees focused on diabetes care innovation. The company's mission centers on making diabetes more manageable through technology, exemplified by products like the MiniMed 780G system. Que Dallara, current EVP and President of Medtronic Diabetes, will serve as CEO of the new standalone company. The separation is expected to occur through capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof. The company's legacy dates back to 1983 when Alfred E. Mann founded the original MiniMed, establishing a 40-year history in transforming diabetes care.

Medtronic (NYSE: MDT) announced its participation in Bernstein's 41st Strategic Decisions Conference on May 29, 2025. Chairman and CEO Geoff Martha will deliver a presentation at 11:00 a.m. EDT, followed by a Q&A session with CFO Thierry Piéton. The event will be webcast live and archived on Medtronic's investor relations website.

Medtronic, headquartered in Galway, Ireland, is a global healthcare technology leader with 95,000+ employees across 150+ countries. The company develops technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems, serving two patients every second worldwide.

Medtronic (MDT) reported strong Q4 FY25 results with revenue of $8.9 billion, up 5.4% organic. Q4 GAAP EPS increased 67% to $0.82, while non-GAAP EPS rose 11% to $1.62. For FY25, revenue reached $33.5 billion, growing 4.9% organic, with GAAP EPS of $3.61 (up 31%) and non-GAAP EPS of $5.49 (up 6%). The company announced three major developments: 1) Plans to separate its Diabetes business into a standalone public company within 18 months, 2) A dividend increase to $0.71 per share (marking the 48th consecutive annual increase), and 3) FY26 guidance projecting ~5% organic revenue growth and non-GAAP EPS of $5.50-$5.60. Strong performance was noted across key franchises, particularly in Cardiac Ablation Solutions which grew nearly 30% in Q4.

Medtronic (NYSE: MDT) has announced plans to separate its Diabetes business into a new standalone company through an IPO and subsequent split-off, expected to complete within 18 months. The Diabetes business, representing 8% of revenue and 4% of segment operating profit in FY2025, will become an independent company led by current EVP Que Dallara. The separation aims to create a more focused Medtronic in high-margin growth markets while establishing an independent leader in diabetes care. Post-separation, Medtronic expects improvements in adjusted gross margin (+50 basis points), operating margins (+100 basis points), and EPS accretion. The new diabetes company will be the only firm offering a complete intensive insulin management ecosystem, with over 8,000 employees worldwide. Medtronic's dividend per share will remain unchanged, and the transaction is expected to be tax-free for shareholders.

Medtronic (NYSE: MDT) has scheduled the release of its fourth quarter and full fiscal year 2025 financial results for Wednesday, May 21, 2025. The company will issue a news release at 5:45 a.m. CDT, followed by a video webcast at 7:00 a.m. CDT to discuss the results. The fiscal year 2025 ended on April 25, 2025.

The healthcare technology leader has also announced its earnings release schedule for fiscal year 2026, with quarterly results planned for August 19, 2025, November 18, 2025, February 17, 2026, and May 20, 2026. Medtronic, headquartered in Galway, Ireland, employs over 95,000 people across 150+ countries, developing technologies that treat 70 health conditions including cardiac devices, surgical robotics, and insulin pumps.

A new Medtronic survey reveals concerning gaps in women's heart health awareness. Despite cardiovascular disease being the #1 killer of women in the U.S., 56% of women have never discussed heart health with their mothers or family members. The survey found that 45% of women were more likely to discuss sensitive topics like politics or money before family heart health history. Notably, 94% of women are responsible for family health decisions, yet 60% struggle to prioritize their own health. Women face significant disparities in heart disease treatment, being 35% less likely to receive minimally invasive solutions for heart valve failure compared to men. The impact is particularly severe among women of color, with 43% of Hispanic women and 59% of Black women experiencing cardiovascular disease. In response, Medtronic launched the 'Letter to My Mother' campaign to encourage heart health conversations and awareness.

Medtronic (NYSE: MDT) announced positive clinical outcomes from two studies using their Affera™ family of technologies for atrial fibrillation treatment. The Sphere-360™ single-shot PFA catheter demonstrated 88% freedom from arrhythmia recurrence and 98% pulmonary vein isolation at one year, with no reported safety events in the optimized waveform group.

The Sphere-9™ catheter showed effectiveness for linear ablation in persistent AFib patients, based on sub-analysis from the Sphere Per-AF IDE study. The device received FDA approval in October 2024. Medtronic plans to begin U.S. pivotal trials for Sphere-360 later this year.

The company currently offers two PFA solutions: the PulseSelect™ system available in over 30 countries, and the Affera system with Sphere-9 catheter available in Europe, Australia, and New Zealand. AFib affects more than 60 million people worldwide and is a progressive disease that increases risks of heart failure, stroke, and death.

Medtronic (NYSE: MDT) announced successful results from its Expand URO clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The study, the largest multi-center prospective Investigational Device Exemption (IDE) trial for multi-port robotic-assisted urologic surgery in the U.S., met both primary safety and effectiveness endpoints.

The trial included 137 patients undergoing urologic procedures. The American Urologic Association (AUA) described it as a 'practice-changing, paradigm-shifting (P2) clinical trial in urology'. Results were presented at the AUA annual meeting in Las Vegas by Dr. Michael R. Abern from Duke University Hospital, the study's national principal investigator.

Medtronic (NYSE: MDT) has received FDA approval for its OmniaSecure™ defibrillation lead, the world's smallest defibrillation lead at 4.7 French (1.6mm). The device is approved for right ventricle placement in adults and pediatric patients aged 12 and up.

The lead, built on the SelectSecure™ Model 3830 pacing lead platform, connects to implantable defibrillators to treat life-threatening heart rhythm conditions. The company also presented investigational study results at Heart Rhythm 2025, showing 100% defibrillation success when the lead is implanted in the left bundle branch (LBB) area.

The LEADR LBBAP clinical study demonstrated a 95.8% successful implantation rate in the first 193 patients, with no procedure-related major complications. The study enrolled approximately 300 patients across 24 sites in 11 countries. The smaller diameter aims to reduce complications such as venous occlusion and tricuspid valve regurgitation.